Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets

Completed · Phase 1

Conditions studied: Healthy

In brief

The purpose of this trial is to demonstrate the relative bioavailability of 2 newly developed fixed dose combinations (FDC) tablets containing empagliflozin \& metformin XR and the single tablets of empagliflozin and metformin XR when administered singularly

Key facts

Study ID

NCT02106923

Run by

Boehringer Ingelheim

People needed

72

Starts

2014-04-01

Expected to finish

2014-07-01

Last updated by the study team

2017-03-09

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy males or females
• Age 18-50 years (incl.)
• Body Mass Index (BMI) 18.5 to 29.9 kg/m2 (incl.)
• Subjects must be able to understand and comply with study requirements

You may not qualify if…

• Any deviation from healthy condition

Where it is running

• Boehringer Ingelheim Investigational Site — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.